Jiangsu Hengrui Pharmaceuticals(600276.SH) received acceptance of the application for the marketing license of SHR4640 tablets.
Hengrui Medicine (600276.SH) announced that the company has received a "Notice of Acceptance" issued by the National Medical Products Administration...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has received the "Acceptance Notification" issued by the National Medical Products Administration. The company's application for the market approval of SHR4640 tablets has been accepted by the national drug regulatory authority. The drug is intended for the long-term treatment of primary gout with hyperuricemia.
Related Articles
In 2026, the new NIO 5566 model will be launched, and the Hong Kong stock market closed at noon skyrocketed by over 9%.
Poly Property (00119) 2025 Annual Report: Continuous optimization of structure, sales among top fifteen
On March 31st, MNSO (09896) spent 396,900 USD to repurchase 98,100 shares.
In 2026, the new NIO 5566 model will be launched, and the Hong Kong stock market closed at noon skyrocketed by over 9%.
Poly Property (00119) 2025 Annual Report: Continuous optimization of structure, sales among top fifteen
On March 31st, MNSO (09896) spent 396,900 USD to repurchase 98,100 shares.
